Keywords
Monoclonal antibody treatment
Fundus diseases
Adverse reactions
Quality of life
Submitted : 2024-02-19
Accepted : 2024-03-05
Published : 2024-03-20
Abstract
Objective: To analyze the effect of triamcinolone acetonide combined with ranibizumab in patients with fundus diseases. Methods: 100 patients with fundus diseases admitted from January 2018 to January 2023 were selected. The patients were separated into two groups according to the random number table method, with 50 cases in the control group (treated with ranibizumab), and 50 cases in the observation group (treated with triamcinolone acetonide combined with ranibizumab). The clinical effects of both treatment regimens were compared. Results: The time taken for symptom disappearance of the observation group was shorter than that of the control group (P < 0.05). The observation group had higher naked-eye visual acuity (4.18 ± 0.89) compared to the control group. Besides, the observation group also had lower intraocular pressure (14.19 ± 1.33 mmHg) and retinal thickness (283.14 ± 3.29 μm), with (P < 0.05) compared to the control group. Moreover, the observation group had a lower adverse reaction rate and a higher quality of life (P < 0.05). Conclusion: The application of triamcinolone acetonide combined with ranibizumab treatment can quickly relieve the clinical symptoms of patients with fundus disease, improve visual acuity, intraocular pressure, and retinal thickness, with low adverse reaction rate and better prognosis and quality of life.
References
Zhan T, Liu W, 2020, Effect of Intravitreal Injection of Ranibizumab Injection in the Treatment of Fundus Diseases. Chinese Contemporary Medicine, 27(29): 146–148 + 155.
Chang H, Qi F, Xu L, et al., 2020, Clinical Effect of Intravitreal Injection of Ranibizumab Injection in the Treatment of Fundus Diseases. Chinese Journal of Misdiagnosis, 15(07): 305–307.
Lan F, Zhang G, He H, et al., 2023, Clinical Analysis and Efficacy Observation of Reactivation of Retinopathy of Prematurity After Intravitreal Ranibizumab Injection. Chinese Journal of Fundus Diseases, 39(6): 471–475.
Sun X, Chen P, Wang X, et al., 2019, Clinical Observation of Intravitreal Injection of Ranibizumab in the Treatment of Retinopathy of Prematurity. Chinese Journal of Practical Ophthalmology, 37(1): 26–29.
Wu Z, Li J, Qi Z, et al., 2019, Effect of Intravitreal Ranibizumab Injection in Treating Fundus Diseases. Chinese Modern Drug Application, 13(5): 6–8.
Guo Q, 2020, Effect of Intravitreal Injection of Ranibizumab Injection in the Treatment of Fundus Diseases. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 30(5): 148–150.
Lin Y, Zhou Q, 2019, Clinical Efficacy of Intravitreal Ranibizumab Injection in Treating Wet Age-Related Macular Degeneration. Chinese Journal of Gerontology, 39(9): 2180–2182.
Liang S, Chen Q, Hu C, et al., 2020, Observation on the Efficacy of Prolonged Photodynamic Therapy Combined with Intravitreal Injection of Ranibizumab in the Treatment of Solitary Choroidal Hemangioma in the Posterior Pole. Chinese Journal of Ophthalmology, 36(2): 116–120.
Zhu C, Pan L, Yi Q, et al., 2022, Effects of Intravitreal Injection of Ranibizumab on the Expression Levels of Cytokines in the Aqueous Humor of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. Chinese Journal of Ophthalmology, 38(9): 739–743.
Li X, Wang Y, Wang L, et al., 2021, Clinical Efficacy Observation and Application Value Analysis of Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Retinopathy. Shanxi Medical Journal, 50(4): 593–595.